Abstract: The invention provides a dispersible solid drug formulation comprising finely divided diclofenac as the free acid, from 5 to 25% by weight of a disintegrant and a pharmaceutically acceptable diluent.

Abstract: The invention relates to compounds of formula I ##STR1## wherein R is hydrogen or C.sub.1 -C.sub.7 alkyl, or wherein R is the structural element-alk-R.sub.1 in which alk is C.sub.1 -C.sub.7 alkylene, C.sub.2 -C.sub.7 alkylidene or C.sub.3 -C.sub.6 cycloalkylidene and R.sub.1 is hydroxy, C.sub.1 -C.sub.7 alkoxy, phenyl-C.sub.1 -C.sub.7 alkoxy or C.sub.2 -C.sub.7 alkanoyloxy;in free form or in the form of a salt; processes for their preparation, their use, and also pharmaceutical compositions comprising a compound of formula I in free form or in the form of a pharmaceutically acceptable salt.

Abstract: Compounds of formula I ##STR1## wherein Z is thiazolyl or isothiazolyl, and X, R, R.sub.0, R.sub.1, R.sub.2 and R.sub.3 are as defined in the description, have valuable pharmaceutical properties and are effective especially against tumors.

Abstract: The invention relates to new benzazole derivatives of the formula I ##STR1## wherein X is oxygen or sulphur, R.sub.1 is lower alkyl, lower alkenyl or cycloalkyl, R.sub.2 and R.sub.3 independently of one another are each hydrogen, lower alkyl or cycloalkyl radicals or taken together are a substituted or unsubstituted bivalent hydrocarbon residue of aliphatic character in which the carbon atoms of the chain may be interrupted by a heteroatom, R.sub.4 is either a group ##STR2## wherein R.sub.5 and R.sub.6 independently of one another are lower alkyl or cycloalkyl radicals, optionally substituted, or taken together R.sub.5 and R.sub.6 are a substituted or unsubstituted bivalent hydrocarbon residue of aliphatic character in which the carbon atoms of the chain may be interrupted by a heteroatom, or, R.sub.4 is a group ##STR3## where R.sub.7 is a lower alkyl group, and their salts and N-oxides. The products are useful as anthelmintic effective agents. The products can be prepared to methods known per se.

Abstract: The invention concerns the use of IgE-binding factor (IgE-bf) for the stimulation of the maturation, i.e. of the differentiation and proliferation, of myeloid precursor cells in context with interleukin-1 (IL-1). The invention further concerns a a pharmaceutical preparation comprising IgE-bf either alone or in combination with IL-1 for the treatment or prevention of diseases by stimulating the maturation of myeloid precursor cells.

Abstract: The compounds of the formula ##STR1## in which one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1 -.sub.8 -alkyl, C.sub.3 -.sub.6 -cycloalkyl, phenyl optionally substituted by halogeno, C.sub.1 -.sub.4 -alkyl, C.sub.1 -.sub.4 -alkoxy and/or trifluoromethyl, or C.sub.7 -.sub.10 -phenylalkyl optionally substituted in the phenyl moiety by halogeno, C.sub.1 -.sub.4 -alkyl, C.sub.1 -.sub.4 -alkoxy and/or trifluormethyl, and the other two are hydrogen, or salts thereof.These compounds have valuable pharmaceutical properties.

Abstract: Compounds of formula I ##STR1## wherein A, X.sub.1, X.sub.2, X.sub.3, X.sub.4, Y, Z and R.sub.1 to R.sub.6 have the meanings given in the description, have valuable pharmaceutical properties and are effective especially against tumours. They are prepared in a manner known per se.

Abstract: The invention concerns a pharmaceutical preparation comprising the 25K IgE-binding factor (25K IgE-bf) and interleukin-1 (IL-1), and the use of said pharmaceutical preparation for the stimulation of the maturation of prothymocytes, e.g. for the treatment of T cell immunodeficiencies and prothymocyte leukemias.

Abstract: Compounds having GABA.sub.B -antagonistic properties, for example those of formula I ##STR1## wherein one of the radicals R.sub.1, R.sub.2 and R.sub.3 is hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another is hydrogen or, in the case of R.sub.1 or R.sub.2, hydroxy or, in the case of R.sub.1, halogen or, in the case of R.sub.2 together with R.sub.2 ', oxo, and the remaining radical is hydrogen, R.sub.1 ' is hydrogen or halogen, R.sub.2 ' is hydrogen, hydroxy or, together with R.sub.2, is oxo, R.sub.4 and R.sub.5 are hydrogen or R.sub.4 is an araliphatic or heteroarylaliphatic radical and R.sub.5 is hydrogen or an aliphatic radical, and R is an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, araliphatic, heteroarylaliphatic or aromatic radical having at least 2 carbon atoms or, when R.sub.1 is hydrogen or hydroxy, R.sub.2 is an aromatic radical and R.sub.1 ', R.sub.2 ' and R.sub.

Abstract: The invention relates to azo compounds, especially to compounds of formula ##STR1## wherein R.sub.1 is lower alkyl, R.sub.2 is lower alkyl, R.sub.3 is hydrogen, carboxy or sulfo, R.sub.4 is carboxy or sulfo, G is an unsubstituted or substituted 1,4-phenylene group or an unsubstituted or substituted 1,4-naphthylene group, and wherein either R.sub.5 and R.sub.6 together are an additional bond and L is an oxygen or sulfur atom or wherein R.sub.5 is hydrogen, R.sub.6 is halomethyl and L is an oxygen atom, and salts thereof, to the use of compounds I and their salts, to a process for the preparation of compounds I and their salts, to starting materials used in that preparation process, and salts thereof, to a process for the preparation of those starting materials and their salts, to a device in which the compounds I and their salts are used, and to a process in which that device is used.

Abstract: Compounds of the formula I ##STR1## in which R.sub.1 is lower alk-2-en-1-yl, lower alk-3-en-2-yl, lower alk-2-yn-1-yl or lower alkyl substituted in the 2,3-position by radicals which can be eliminated to give a double bond, R.sub.2 is hydrogen and R.sub.3 is methyl which is unsubstituted or substituted by radicals which can be eliminated together with hydrogen R.sub.2 to give a double bond or R.sub.2 and R.sub.3 are both hydrogen or lower alkyl or are together methylene and R.sub.4 is a group of the formula Ia, Ib or Ic ##STR2## in which R.sub.5 is hydrogen, lower alkyl, lower alk-2-en-1-yl or lower alk-2-yn-1-yl and R.sub.6 is a group of the formula Id or Ie ##STR3## in which R.sub.1, R.sub.2, R.sub.3 and R.sub.5 are as defined, and their pharmaceutically acceptable salts can be used in a novel manner for the treatment of diseases of the rheumatoid type.

Abstract: Compounds of formula I ##STR1## wherein Z, R, R.sub.1, R.sub.2 and X are as defined in the description, have valuable pharmaceutical properties and are effective especially against tumours. They are prepared in a manner known per se.

Abstract: A Milk Growth Factor (MGF) obtained from milk, methods for its isolation and purification from milk or milk products, pharmaceutical compositions, food compositions and cell growth media comprising the factor and the uses thereof for treating trauma in mammals, suppressing the immune response, treating cancer, stimulating growth of mammals and cell cultures.

Abstract: A light diffuser for simultaneous photodynamic therapy and hyperthermic treatment in the oesophagus has an arrangement (14 to 18) which disperses radially the light (10) fed in by way of an optical fiber (6) and has a tube (12) filled with silicone to which are added concentrations, modulated in the axial direction, of quartz grains having a diameter of approximately 40 .mu.m which bring about a refraction having little dependence on the wavelength.

Abstract: The invention relates to an improved process for the preparation of compounds of formula ##STR1## or salts thereof, starting from compounds of formulae ##STR2## via compounds of formulae ##STR3## in which compounds R.sub.1 is hydrogen or lower alkyl, R.sub.2 is an organic radical which may carry a functional group which may be protected by a customary protective group R.sub.2.sup.o, R.sub.3 is hydrogen or a customary carboxyl protective group R.sub.3.sup.o, W is a group which can be replaced by a thiocarboxylic acid radical of formula III, and Z is oxygen or sulfur.

Abstract: The invention relates to a solid, rapidly disintegrating dosage form in the form of effervescent tablets for producing an aqueous suspension of diclofenac for peroral administration. The dosage form contains diclofenac in micronised form provided with a permeable, swellable coating, together with pharmaceutical excipients.

Abstract: Compounds of formula I ##STR1## wherein the dotted line, Az, Z, R.sub.1 and R.sub.2 are as defined in the description, have valuable pharmaceutical properties and are effective especially against tumors. They are prepared in a manner known per se.

Abstract: The invention provides an antidote to blood anticoagulants comprising Factor VIII or fragments of Factor VIII which retain its activity or a substance which increases its concentration in blood.

Abstract: Tbe invention relates to 3H-1,2,3-triazolo[4,5-d]pyrimidine derivatives, especially substituted 3-benzyl-3H-1,2,3-triazolo[4,5-d]-pyrimidines of the general formula ##STR1## in which Ph represents a phenyl radical substituted by halogen, lower alkyl, trifluoromethyl and/or by cyano, R.sub.1 represents a free amino group or an amino group that is substituted aliphatically, cycloaliphatically, cycloaliphatically-aliphatically and/or by acyl, and R.sub.2 represents hydrogen, lower alkyl, a free amino group, or an amino group that is substituted aliphatically, cycloaliphaically, cycloaliphatically-aliphatically and/or by acyl, in free form or in form of a salt, with the proviso, that in a compound of formula I in free form, wherein R.sub.1 represents N,N-di-C.sub.1 -C.sub.6 -alkylamino in which the two N-C.sub.1 -C.sub.6 -alkyl groups may be the same or different, N-mono-C.sub.1 -C.sub.6 -alkylamino or amino, R.sub.2 is other than hydrogen and other than C.sub.1 - C.sub.

Abstract: Benzoheterocyclylalkylaminoalkanediphosphonic acids of formula I ##STR1## wherein R.sub.1 and R.sub.2, independently of one another, are hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl, R.sub.3 is hydrogen or lower alkyl, X and Y, independently of one another, are oxy or thio, alk.sub.1 and alk.sub.2 are identical or different lower alkylene radicals, n is 0 or 1 and m and m', independently of one another, are 0, 1 or 2, the sum of n, m and m' being 1, 2 or 3, and their salts exhibit a pronounced regulatory action on the calcium metabolism of warm-blooded animals. They are prepared, for example, as follows: in a compound of the formula ##STR2## wherein R.sub.1, R.sub.2, n, m, m', X, Y, alk.sub.1 and alk.sub.2 are as defined above, R'.sub.3 is one of the groups R.sub.3 mentioned above or is an amino-protecting group R.sub.0, Z.sub.1 is a functionally modified phosphono group, and Z.sub.2 is a free or functionally modified phosphono group, converting functionally modified phosphono Z.sub.